All questions
Every question has a deadline, a criterion written in advance, and a designated resolution source.
AI & tech — 27
Medicine — 78
Will the FDA approve bepirovirsen for chronic hepatitis B?68% · deadline 2026-10-26Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?97% · deadline 2026-10-31Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?81% · deadline 2026-11-13Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?86% · deadline 2026-11-15Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?55% · deadline 2026-11-27Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?49% · deadline 2026-11-30Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?58% · deadline 2026-11-30Will the FDA approve imsidolimab for generalized pustular psoriasis?44% · deadline 2026-12-12Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?65% · deadline 2026-12-15Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?81% · deadline 2026-12-15Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?45% · deadline 2026-12-17Will the FDA approve lorundrostat for hypertension?63% · deadline 2026-12-22Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?30% · deadline 2026-12-23Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?83% · deadline 2026-12-24Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?83% · deadline 2026-12-30Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?81% · deadline 2026-12-30Will the CHMP issue a positive opinion on narsoplimab following re-examination before 31 December 2026?6% · deadline 2026-12-31Will the FDA approve CagriSema for weight management before 31 December 2026?38% · deadline 2026-12-31Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?57% · deadline 2026-12-31Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?46% · deadline 2026-12-31Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?68% · deadline 2026-12-31Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?58% · deadline 2026-12-31Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?65% · deadline 2027-01-15Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?80% · deadline 2027-01-27Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?74% · deadline 2027-01-29Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?66% · deadline 2027-01-31 · RESOLVED : OUIWill NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?68% · deadline 2027-02-03Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?73% · deadline 2027-02-15Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?82% · deadline 2027-03-06Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?54% · deadline 2027-03-13Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?80% · deadline 2027-03-13Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?74% · deadline 2027-03-14Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?87% · deadline 2027-03-14Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?59% · deadline 2027-03-24Will the FDA approve Aquestive Therapeutics's dibutepinephrine (Anaphylm) for treatment of Type I allergic reactions, including anaphylaxis by March 30, 2027?81% · deadline 2027-03-30Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?75% · deadline 2027-03-31Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?68% · deadline 2027-03-31Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?78% · deadline 2027-03-31Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?80% · deadline 2027-04-28Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?63% · deadline 2027-04-29Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?58% · deadline 2027-04-30Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?52% · deadline 2027-04-30Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?75% · deadline 2027-05-01Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?67% · deadline 2027-05-01Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?78% · deadline 2027-05-05Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?89% · deadline 2027-05-07Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?80% · deadline 2027-05-28Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?68% · deadline 2027-05-30Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?43% · deadline 2027-05-30Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?52% · deadline 2027-05-30Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?70% · deadline 2027-05-31Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?36% · deadline 2027-05-31Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?39% · deadline 2027-06-04Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?86% · deadline 2027-06-10Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?61% · deadline 2027-06-15Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?65% · deadline 2027-06-16Will the CHMP issue an opinion on apitegromab in spinal muscular atrophy before 30 June 2027?62% · deadline 2027-06-30Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?72% · deadline 2027-06-30Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?81% · deadline 2027-06-30Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?60% · deadline 2027-07-30Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?36% · deadline 2027-07-30Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?45% · deadline 2027-07-31Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?87% · deadline 2027-07-31Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?70% · deadline 2027-07-31Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?53% · deadline 2027-08-17Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?58% · deadline 2027-08-20Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?85% · deadline 2027-09-30Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?52% · deadline 2027-10-30Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?84% · deadline 2027-12-31Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?36% · deadline 2027-12-31Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?65% · deadline 2028-01-30Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?39% · deadline 2028-03-29Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?47% · deadline 2028-05-21Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?58% · deadline 2028-05-30Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?34% · deadline 2029-05-30Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?48% · deadline 2029-06-30Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?40% · deadline 2029-07-01Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?56% · deadline 2032-06-30 Quantum — 13
Deep tech — 7
Finance — 9
M&A — 4
Climat — 5